XM does not provide services to residents of the United States of America.
E
E

Elekta

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Arkema, Flatexdegiro, Mediobanca

EUROPE RESEARCH ROUNDUP-Arkema, Flatexdegiro, Mediobanca Oct 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Arkema, Flatexdegiro and Mediobanca, on Thursday. HIGHLIGHTS * Arkema SA AKE.PA : Berenberg raises to buy from hold * Flatexdegiro AG FTKn.DE : Goldman Sachs raises to buy from neutral * Mediobanca MDBI.MI : Deutsche Bank raises to hold from sell * Orsted ORSTED.CO : Deutsche Bank cuts to hold from buy * Syensqo NV SYENS.
A
A
A
A
A
B
B
B
B
B
C
C
C
C
D
E
G
L
M
M
M
N
O
P
R
S
S
S
U
U
V
W
A
D
S
W

Elekta Issues SEK 1.5 Bln Bond, Signs Revolving Credit Facility Of Sek 1 Bln

BRIEF-Elekta Issues SEK 1.5 Bln Bond, Signs Revolving Credit Facility Of Sek 1 Bln Oct 1 (Reuters) - Elekta AB (publ) EKTAb.ST : ISSUES A SEK 1.5 BILLION BOND AND SIGNS A REVOLVING CREDIT FACILITY OF SEK 1 BILLION Source text for Eikon: ID:nMFN7n2xCL Further company coverage: [EKTAb.ST] (Gdansk Newsroom)
E

Elekta Evo Submitted To U.S. FDA For Premarket Approval

BRIEF-Elekta Evo Submitted To U.S. FDA For Premarket Approval Sept 24 (Reuters) - Elekta AB (publ) EKTAb.ST : ELEKTA EVO SUBMITTED TO U.S. FDA FOR PREMARKET APPROVAL – TO BE FEATURED AT ASTRO Source text for Eikon: ID:nMFN23wkl1 Further company coverage: [EKTAb.ST] (Gdansk Newsroom)
E

Elekta Evo Is Available For Sale, Marketing In Europe

BRIEF-Elekta Evo Is Available For Sale, Marketing In Europe Sept 18 (Reuters) - Elekta AB (publ) EKTAb.ST : ELEKTA’S AI-POWERED ADAPTIVE CT-LINAC, ELEKTA EVO, RECEIVES CE MARK AI-POWERED ADAPTIVE CT-LINEAR ACCELERATOR, ELEKTA EVO, IS AVAILABLE FOR SALE AND MARKETING IN EUROPE, HAVING RECEIVED CE MARK Source text for Eikon: ID:nMFN1n7fvc Further c
E

Banco, Shell, WH Smith

EUROPE RESEARCH ROUNDUP-Banco, Shell, WH Smith Sept 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco, Shell and WH Smith on Thursday. HIGHLIGHTS * ABN Amro Bank NV ABNd.AS : JP Morgan raises to neutral from underweight * Banco Bpm BAMI.MI : JP Morgan raises to neutral from underweight * Shell Plc SHEL.L : Berenberg cuts target price to 3,100p from 3,400p * UMG UMG.AS : Citigroup cuts target price to EUR 26 from EUR 29.50 *
A
B
B
B
C
C
C
C
D
D
D
D
E
E
E
E
I
I
I
N
O
P
R
R
R
S
S
W
P
A
B
B
F
L
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.